This study looked at the safety and effectiveness of Aztreonam for Inhalation Solution versus Tobramycin Nebulizer Solution in adult and pediatric cystic fibrosis (CF) patients aged 6 years or older with pulmonary Pseudomonas aeruginosa (PA) infection.

ELIGIBILITY

Age:

>= 6 Years

FEV1:

1 - 75 Percent Predicted

P. aeruginosa status:

Positive

B. cepacia status:

Negative

Other Primary Eligibility Requirements:

Note: Detailed eligibility criteria information may be available on clinicaltrials.gov. If a specific
trial listing for this trial is available, a link to the specific clinicaltrials.gov listing will be present in the "More Information" section below.